NYSE · CIK 0001524472
XYL Xylem Inc.
Insider trading from SEC Form 4. Last filing 2 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at Xylem Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 45Moderate | sell | Dorothy Trefon Capers SVP & General Counsel | $1.5M | 12,026 | -60% | - | |
| 10Weak | buy | Lila Tretikov director | $528 | 4 | +0% | - | |
| 15Weak | sell | Lila Tretikov director | $480 | 4 | -0% | - |
Transactions
The last 34 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Geri-Michelle McShane SVP, CAO | AGrant or award Common Stock | +4,257 | $0.00 | $0 | 7,862 | 2 d ago |
| Mar 5, 2025 | Rodney Aulick SVP & President, WSS | AGrant or award Common Stock | +1,639 | $129.67 | $213k | 75,774 | Mar 6, 2025 |
| Mar 4, 2025 | Dorothy Trefon Capers SVP & General Counsel | MOption exercise Common Stock | +7,868 | $86.76 | $683k | 15,883 | Mar 6, 2025 |
| Mar 5, 2025 | William K Grogan SVP & Chief Financial Officer | AGrant or award Common Stock | +4,338 | $129.67 | $563k | 32,415 | Mar 6, 2025 |
| Mar 5, 2025 | Meredith Emmerich SVP & Pres, AW | AGrant or award Common Stock | +1,060 | $129.67 | $137k | 4,833 | Mar 6, 2025 |
| Mar 5, 2025 | Albert Cho SVP, Strategy | AGrant or award Common Stock | +1,060 | $129.67 | $137k | 13,970 | Mar 6, 2025 |
| Mar 5, 2025 | Albert Cho SVP, Strategy | AGrant or award Non-Qualified Stock Options (Right to buy)derivative | +3,721 | $129.67 | $483k | 3,721 | Mar 6, 2025 |
| Mar 5, 2025 | Meredith Emmerich SVP & Pres, AW | AGrant or award Non-Qualified Stock Options (Right to buy)derivative | +3,721 | $129.67 | $483k | 3,721 | Mar 6, 2025 |
| Mar 5, 2025 | William K Grogan SVP & Chief Financial Officer | AGrant or award Non-Qualified Stock Options (Right to buy)derivative | +15,223 | $129.67 | $2.0M | 15,223 | Mar 6, 2025 |
| Mar 5, 2025 | Rodney Aulick SVP & President, WSS | AGrant or award Non-Qualified Stock Options (Right to buy)derivative | +5,751 | $129.67 | $746k | 5,751 | Mar 6, 2025 |
| Mar 4, 2025 | Dorothy Trefon Capers SVP & General Counsel | MOption exercise Common Stock | +4,158 | $101.09 | $420k | 20,041 | Mar 6, 2025 |
| Mar 4, 2025 | Dorothy Trefon Capers SVP & General Counsel | SOpen-market sale Common Stock | -12,026 | $127.26 | $1.5M | 8,015 | Mar 6, 2025 |
| Mar 5, 2025 | Dorothy Trefon Capers SVP & General Counsel | AGrant or award Common Stock | +1,398 | $129.67 | $181k | 9,413 | Mar 6, 2025 |
| Mar 4, 2025 | Dorothy Trefon Capers SVP & General Counsel | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative | -4,158 | $0.00 | $0 | 2,079 | Mar 6, 2025 |
| Mar 4, 2025 | Dorothy Trefon Capers SVP & General Counsel | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative | -7,868 | $0.00 | $0 | 0 | Mar 6, 2025 |
| Mar 5, 2025 | Dorothy Trefon Capers SVP & General Counsel | AGrant or award Non-Qualified Stock Options (Right to buy)derivative | +4,905 | $129.67 | $636k | 4,905 | Mar 6, 2025 |
| Mar 1, 2025 | William K Grogan SVP & Chief Financial Officer | FTax withholding Common Stock | -396 | $129.78 | $51k | 28,077 | Mar 4, 2025 |
| Mar 1, 2025 | Dorothy Trefon Capers SVP & General Counsel | AGrant or award Common Stock | +1,315 | $129.78 | $171k | 7,197 | Mar 4, 2025 |
| Mar 1, 2025 | Albert Cho SVP, Strategy | AGrant or award Common Stock | +737 | $129.78 | $96k | 12,443 | Mar 4, 2025 |
| Mar 1, 2025 | Rodney Aulick SVP & President, WSS | FTax withholding Common Stock | -166 | $129.78 | $22k | 74,135 | Mar 4, 2025 |
| Mar 1, 2025 | Dorothy Trefon Capers SVP & General Counsel | AGrant or award Common Stock | +1,575 | $129.78 | $204k | 8,772 | Mar 4, 2025 |
| Mar 1, 2025 | Albert Cho SVP, Strategy | AGrant or award Common Stock | +882 | $129.78 | $114k | 13,325 | Mar 4, 2025 |
| Mar 1, 2025 | Dorothy Trefon Capers SVP & General Counsel | AGrant or award Common Stock | +1,575 | $129.78 | $204k | 10,347 | Mar 4, 2025 |
| Mar 1, 2025 | Albert Cho SVP, Strategy | AGrant or award Common Stock | +882 | $129.78 | $114k | 14,207 | Mar 4, 2025 |
| Mar 1, 2025 | Dorothy Trefon Capers SVP & General Counsel | FTax withholding Common Stock | -1,516 | $129.78 | $197k | 8,831 | Mar 4, 2025 |
| Mar 1, 2025 | Albert Cho SVP, Strategy | FTax withholding Common Stock | -918 | $129.78 | $119k | 13,289 | Mar 4, 2025 |
| Mar 1, 2025 | Dorothy Trefon Capers SVP & General Counsel | FTax withholding Common Stock | -816 | $129.78 | $106k | 8,015 | Mar 4, 2025 |
| Mar 1, 2025 | Albert Cho SVP, Strategy | FTax withholding Common Stock | -379 | $129.78 | $49k | 12,910 | Mar 4, 2025 |
| Jan 2, 2025 | Rodney Aulick SVP & President, WSS | FTax withholding Common Stock | -1,316 | $116.02 | $153k | 74,301 | Jan 3, 2025 |
| Dec 16, 2024 | Rodney Aulick SVP & President, WSS | FTax withholding Common Stock | -1,558 | $120.60 | $188k | 75,448 | Dec 17, 2024 |
| Oct 22, 2024 | Lila Tretikov director | POpen-market purchase Common Stock | +4 | $131.98 | $528 | 7,384 | Dec 2, 2024 |
| Nov 1, 2024 | Lila Tretikov director | SOpen-market sale Common Stock | -4 | $119.96 | $480 | 7,380 | Dec 2, 2024 |
| Oct 21, 2024 | Meredith Emmerich SVP & Pres, AW | AGrant or award Common Stock | +3,772 | $132.54 | $500k | 3,772 | Oct 23, 2024 |
| Oct 21, 2024 | Meredith Emmerich SVP & Pres, AW | AGrant or award Stock Options (Right to buy)derivative | +33,138 | $132.54 | $4.4M | 33,138 | Oct 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Rodney AulickSVP & President, WSS
- Dorothy Trefon CapersSVP & General Counsel
- Albert ChoSVP, Strategy
- Meredith EmmerichSVP & Pres, AW
- William K GroganSVP & Chief Financial Officer
- Geri-Michelle McShaneSVP, CAO
- Lila Tretikovdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.